Nordwand Advisors, LLC Gilead Sciences, Inc. Transaction History
Nordwand Advisors, LLC
- $374 Billion
- Q3 2024
A detailed history of Nordwand Advisors, LLC transactions in Gilead Sciences, Inc. stock. As of the latest transaction made, Nordwand Advisors, LLC holds 200 shares of GILD stock, worth $17,952. This represents 0.0% of its overall portfolio holdings.
Number of Shares
200
Previous 200
-0.0%
Holding current value
$17,952
Previous $13.7 Million
22.2%
% of portfolio
0.0%
Previous 0.01%
Shares
1 transactions
Others Institutions Holding GILD
# of Institutions
1,924Shares Held
994MCall Options Held
10.5MPut Options Held
9.75M-
Black Rock Inc. New York, NY121MShares$10.8 Billion0.19% of portfolio
-
Vanguard Group Inc Valley Forge, PA115MShares$10.4 Billion0.18% of portfolio
-
Capital World Investors Los Angeles, CA76.5MShares$6.87 Billion1.03% of portfolio
-
Capital Research Global Investors Los Angeles, CA61.8MShares$5.55 Billion1.12% of portfolio
-
State Street Corp Boston, MA60.2MShares$5.4 Billion0.21% of portfolio
About GILEAD SCIENCES, INC.
- Ticker GILD
- Exchange NASDAQ
- Sector Healthcare
- Industry Drug Manufacturers—General
- Shares Outstandng 1,253,369,984
- Market Cap $113B
- Description
- Gilead Sciences, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, and Atripla products for the treatment of HIV/AIDS; Veklury, a...